Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TJ 0113

Next Previous
Drug Profile

TJ 0113

Alternative Names: TJ-0113

Latest Information Update: 13 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hangzhou PhecdaMed
  • Class Anti-inflammatories; Antiparkinsonians; Small molecules
  • Mechanism of Action Autophagy stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease
  • Phase I Hereditary nephritis

Most Recent Events

  • 10 Jun 2025 Hangzhou PhecdaMed plans interventional clinical trial in Deafness and Hearing loss in China (NCT07012746)
  • 09 Jun 2025 Hangzhou PhecdaMed plans a phase II trial for Depressive disorders in China (PO, Capsule) in June 2025 (NCT07018245)
  • 10 Feb 2025 Hangzhou PhecdaMed plans a phase I pharmacokinetic trial (In volunteers) in February 2025 (NCT06832540)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top